Abstract: Background: There is limited knowledge on international trends in topical calcineurin inhibitor (TCI) utilization.
Objective: To describe international TCI utilization trends from 2012 to 2019 and evaluate the relationship of country-level economic status, geographic location, and atopic dermatitis (AD) disease burden with drug utilization.
Methods: We used IQVIA MIDAS® pharmaceutical quarterly sales data to attain country-level purchasing of TCIs in grams from 2012 to 2019. A multivariable linear regression estimated the association between countries’ sociodemographic index (SDI), AD disability-adjusted life year (DALY) rates, and geographic location with TCI utilization.
Results: A total of 68 countries were included in our analysis. From 2012 to 2019, overall TCI utilization increased by 66% but remained 11.2 times higher in high-sociodemographic compared with low-middle/low-sociodemographic countries. SDI and geographic location were associated with greater TCI utilization in multivariable analyses, whereas AD DALY rates were not. High-SDI countries used 21,476 grams (95% confidence interval [CI]: 11,915 to 31,036) and high-middle SDI countries used 9,403 grams (95% CI: −393 to 19,200) more TCIs per 100,000 people compared with low-middle/low-SDI countries, respectively. Northern hemisphere countries used 8,588 grams more TCIs per 100,000 people (95% CI: 612 to 16,564).
Conclusions: We demonstrated greater TCI utilization among high-SDI compared with lower SDI countries.
Get full access to this article
View all access options for this article.
References
1.
MosamA, ToddG. Global epidemiology and disparities in atopic dermatitis. Br J Dermatol. 2023; 188(6):726–737; doi: 10.1093/BJD/LJAD042
2.
HadiHA, TarmiziAI, KhalidKA, et al.The epidemiology and global burden of atopic dermatitis: A narrative review. Life (Basel). 2021; 11(9); doi: 10.3390/LIFE11090936
3.
NuttenS. Atopic dermatitis: Global epidemiology and risk factors. Ann Nutr Metab. 2015; 66(Suppl. 1):8–16; doi: 10.1159/000370220
4.
PengC, YuN, DingY, et al.Epidemiological variations in global burden of atopic dermatitis: An analysis of trends from 1990 to 2019. Allergy. 2022; 77(9):2843–2845; doi: 10.1111/ALL.15380
5.
LaughterMR, MaymoneMBC, MashayekhiS, et al.The global burden of atopic dermatitis: Lessons from the global burden of disease Study 1990-2017. Br J Dermatol. 2021; 184(2):304–309; doi: 10.1111/BJD.19580
6.
UrbanK, ChuS, GieseyRL, et al.The global, regional, and national burden of atopic dermatitis in 195 countries and territories: An ecological study from the global burden of disease study 2017. JAAD Int. 2021; 2:12–18; doi: 10.1016/J.JDIN.2020.10.002
7.
XuF, YanS, LiF, et al.Prevalence of childhood atopic dermatitis: An urban and rural community-based study in Shanghai, China. PLoS One. 2012; 7(5):e36174; doi: 10.1371/JOURNAL.PONE.0036174
8.
EichenfieldLF, TomWL, BergerTG, et al.Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014; 71(1):116–132; doi: 10.1016/J.JAAD.2014.03.023
XueY, BaoW, ZhouJ, et al.Global burden, incidence and disability-adjusted life-years for dermatitis: A systematic analysis combined with socioeconomic development status, 1990-2019. Front Cell Infect Microbiol. 2022; 12:861053; doi: 10.3389/FCIMB.2022.861053
12.
GieseyRL, MehrmalS, UppalP, et al.The global burden of skin and subcutaneous disease: A longitudinal analysis from the global burden of disease Study from 1990-2017. Ski J Cutan Med. 2021; 5(2):125–136; doi: 10.25251/SKIN.5.2.7
13.
AbbafatiC, MachadoDB, CislaghiB, et al.Global age-sex-specific fertility, mortality, Healthy Life Expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: A comprehensive demographic analysis for the global burden of disease Study 2019. Lancet (London, England). 2020; 396(10258):1160–1203; doi: 10.1016/S0140-6736(20)30977-6
Statistical Quality Assurance applied to IQVIA’s Information Offerings 2022 ACTS Annual Report Global Data Science and Advanced Analytics (v20230228). 2023.
Lopez CarreraYI, Al HammadiA, HuangYH, et al.Epidemiology, diagnosis, and treatment of atopic dermatitis in the developing countries of Asia, Africa, Latin America, and the Middle East: A Review. Dermatol Ther (Heidelb). 2019; 9(4):685–705; doi: 10.1007/S13555-019-00332-3
21.
LugerT, BoguniewiczM, CarrW, et al.Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015; 26(4):306–315; doi: 10.1111/PAI.12331
22.
LeeJH, KwonHS, JungHM, et al.Treatment outcomes of topical calcineurin inhibitor therapy for patients with Vitiligo: A systematic review and meta-analysis. JAMA Dermatol. 2019; 155(8):929–938; doi: 10.1001/JAMADERMATOL.2019.0696
23.
LamM, ZhuJW, TadrousM, et al.Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: A systematic review and meta-analysis. JAMA Dermatol. 2021; 157(5):549–558; doi: 10.1001/JAMADERMATOL.2021.0345
24.
TsaiTF, RajagopalanM, ChuCY, et al.Burden of atopic dermatitis in Asia. J Dermatol. 2019; 46(10):825–834; doi: 10.1111/1346-8138.15048
25.
ZinkA, ArentsB, Fink-WagnerA, et al.Out-of-pocket costs for individuals with atopic eczema: A cross-sectional study in nine European countries. Acta Derm Venereol. 2019; 99(3):263–267; doi: 10.2340/00015555-3102
26.
NiessenLW, MohanD, AkuokuJK, et al.Tackling socioeconomic inequalities and non-communicable diseases in low-income and middle-income countries under the Sustainable Development agenda. Lancet. 2018; 391(10134):2036–2046; doi: 10.1016/S0140-6736(18)30482-3
27.
SchrödersJ, WallS, HakimiM, et al.How is Indonesia coping with its epidemic of chronic noncommunicable diseases? A systematic review with meta-analysis. PLoS One. 2017; 12(6):e0179186; doi: 10.1371/JOURNAL.PONE.0179186
CalovM, AlinaghiF, HamannCR, et al.The association between season of birth and atopic dermatitis in the northern hemisphere: A systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2020; 8(2):674–680.e5; doi: 10.1016/J.JAIP.2019.10.007
30.
FonnS, RayS, BlaauwD. Innovation to improve health care provision and health systems in sub-Saharan Africa—promoting agency in mid-level workers and district managers. Glob Public Health. 2011; 6(6):657–668; doi: 10.1080/17441692.2010.489905
31.
LeeJ, KimT, CheonSJ, et al.Prescription patterns of topical medications in patients with atopic dermatitis: An investigative review using big data from the national health insurance corporation. Ann Dermatol. 2023; 35(2):124–131; doi: 10.5021/AD.22.114
32.
EmanuelEJ, ZhangC, GlickmanA, et al.Drug reimbursement regulation in 6 peer countries. JAMA Intern Med. 2020; 180(11):1510–1517; doi: 10.1001/JAMAINTERNMED.2020.4793
33.
SethD, CheldizeK, BrownD, et al.Global burden of skin disease: Inequities and innovations. Curr Dermatol Rep. 2017; 6(3):204–210; doi: 10.1007/S13671-017-0192-7
34.
BajwaH, BaghchechiM, MujahidM, et al.Mixed evidence on the relationship between socioeconomic position and atopic dermatitis: A systematic review. J Am Acad Dermatol. 2022; 86(2):399–405; doi: 10.1016/J.JAAD.2021.09.018
35.
KimY, BlombergM, Rifas-ShimanSL, et al.Racial/ethnic differences in incidence and persistence of childhood atopic dermatitis. J Invest Dermatol. 2019; 139(4):827–834; doi: 10.1016/J.JID.2018.10.029
36.
LePoidevinLM, LeeDE, ShiVY. A comparison of international management guidelines for atopic dermatitis. Pediatr Dermatol. 2019; 36(1):36–65; doi: 10.1111/PDE.13678
37.
PrasadS, BassettIV, FreemanEE. Dermatology on the global stage: The role of dermatologists in international health advocacy and COVID-19 research. Int J Women’s Dermatology. 2021; 7(5Part A):653; doi: 10.1016/J.IJWD.2021.10.003
38.
FreemanEE, LesterJ, PadoveseV, et al.Introducing the global health and equity section in the British Journal of dermatology. Br J Dermatol. 2022; 186(2):201–202; doi: 10.1111/BJD.20898
39.
SchutteAE, JafarTH, PoulterNR, et al.Addressing global disparities in blood pressure control: Perspectives of the international society of hypertension. Cardiovasc Res. 2023; 119(2):381–409; doi: 10.1093/CVR/CVAC130
40.
ZhaoD. Epidemiological features of cardiovascular disease in Asia. JACC Asia. 2021; 1(1):1–13; doi: 10.1016/J.JACASI.2021.04.007
41.
DanaeiG, FinucaneMM, LinJK, et al.National, regional, and global trends in systolic blood pressure since 1980: Systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. Lancet (London, England). 2011; 377(9765):568–577; doi: 10.1016/S0140-6736(10)62036-3
42.
LambojonK, ChangJ, SaeedA, et al.Prices, availability and affordability of medicines with value-added tax exemption: A cross-sectional survey in the Philippines. IJERPH. 2020; 17(14):5242; doi: 10.3390/IJERPH17145242
43.
DruckerAM, WangAR, QureshiAA. Research gaps in quality of life and economic burden of atopic dermatitis: The national eczema association burden of disease audit. JAMA Dermatol. 2016; 152(8):873–874; doi: 10.1001/JAMADERMATOL.2016.1978
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
